{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:46:38Z","timestamp":1780364798110,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA16056"],"award-info":[{"award-number":["CA16056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Szefel Foundation"},{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nancy C. Cully Endowment for Leukemia Research"},{"name":"Leonard S. LuVullo Endowment for Leukemia Research"},{"name":"Callisto Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clml.2013.03.015","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T08:05:22Z","timestamp":1370851522000},"page":"430-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phase I\/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"13","author":[{"given":"Meir","family":"Wetzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thompson L.","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.03.015_bib1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2013.03.015_bib2","first-page":"841","article-title":"FDA approves liposomal vincristine (Marqibo) for rare leukemia","volume":"26","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2013.03.015_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2001-12-0371","article-title":"MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia","volume":"100","author":"Tafuri","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.015_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0163-7258(93)90007-Z","article-title":"Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach","volume":"60","author":"Priebe","year":"1993","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2013.03.015_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.V88.2.633.bloodjournal882633","article-title":"The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines","volume":"88","author":"Consoli","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.015_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s002800000177","article-title":"Phase I study of liposomal annamycin","volume":"46","author":"Booser","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2013.03.015_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00280-002-0464-0","article-title":"Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer","volume":"50","author":"Booser","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2013.03.015_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.015_bib9","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.015_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14712590802586058","article-title":"Pegasparaginase: where do we stand?","volume":"9","author":"Zeidan","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2013.03.015_bib11","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.015_bib12","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.015_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1006216001681","article-title":"Phase I study of liposomal daunorubicin in patients with acute leukemia","volume":"17","author":"Cortes","year":"1999","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2013.03.015_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00277-002-0509-9","article-title":"Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia","volume":"81","author":"Russo","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.03.015_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.thj.6200222","article-title":"High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia","volume":"4","author":"Offidani","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2013.03.015_bib16","first-page":"4260","article-title":"Anthracycline antibiotics with high liposome entrapment: structural features and biological activity","volume":"50","author":"Perez-Soler","year":"1990","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:30Z","timestamp":1761870270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S2152265013001158"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}